Compare MLKN & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLKN | CRVS |
|---|---|---|
| Founded | 1905 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 1994 | 2016 |
| Metric | MLKN | CRVS |
|---|---|---|
| Price | $17.35 | $18.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.17 |
| AVG Volume (30 Days) | ★ 1.1M | 1.1M |
| Earning Date | 03-25-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.31% | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $3,669,900,000.00 | N/A |
| Revenue This Year | $5.94 | N/A |
| Revenue Next Year | $3.78 | N/A |
| P/E Ratio | $17.77 | ★ N/A |
| Revenue Growth | ★ 1.14 | N/A |
| 52 Week Low | $13.77 | $3.17 |
| 52 Week High | $23.18 | $26.95 |
| Indicator | MLKN | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 55.61 | 64.18 |
| Support Level | $16.55 | $16.15 |
| Resistance Level | $17.77 | $18.73 |
| Average True Range (ATR) | 0.60 | 1.02 |
| MACD | 0.45 | 0.39 |
| Stochastic Oscillator | 81.70 | 70.07 |
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.